GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Cryosite Ltd (ASX:CTE) » Definitions » EV-to-FCF

Cryosite (ASX:CTE) EV-to-FCF

: 18.87 (As of Today)
View and export this data going back to 2002. Start your Free Trial

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cryosite's Enterprise Value is A$35.40 Mil. Cryosite's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$1.88 Mil. Therefore, Cryosite's EV-to-FCF for today is 18.87.

The historical rank and industry rank for Cryosite's EV-to-FCF or its related term are showing as below:

ASX:CTE' s EV-to-FCF Range Over the Past 10 Years
Min: -125.98   Med: 11.41   Max: 334.64
Current: 14.84

During the past 13 years, the highest EV-to-FCF of Cryosite was 334.64. The lowest was -125.98. And the median was 11.41.

ASX:CTE's EV-to-FCF is ranked better than
65.71% of 105 companies
in the Medical Diagnostics & Research industry
Industry Median: 24.36 vs ASX:CTE: 14.84

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-19), Cryosite's stock price is A$0.795. Cryosite's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.032. Therefore, Cryosite's PE Ratio for today is 24.84.


Cryosite EV-to-FCF Historical Data

The historical data trend for Cryosite's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cryosite Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-FCF
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.82 8.92 173.13 15.81 24.73

Cryosite Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 15.81 - 24.73 -

Competitive Comparison

For the Diagnostics & Research subindustry, Cryosite's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cryosite EV-to-FCF Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Cryosite's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Cryosite's EV-to-FCF falls into.



Cryosite EV-to-FCF Calculation

Cryosite's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=35.404/1.876
=18.87

Cryosite's current Enterprise Value is A$35.40 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cryosite's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$1.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cryosite  (ASX:CTE) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Cryosite's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.795/0.032
=24.84

Cryosite's share price for today is A$0.795.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cryosite's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.032.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Cryosite EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Cryosite's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cryosite (ASX:CTE) Business Description

Traded in Other Exchanges
N/A
Address
13a Ferndell Street, South Granville, Sydney, NSW, AUS, 2142
Cryosite Ltd is engaged in the provision of supply chain logistics, management of pharmaceutical products used in clinical trials. The company's operating segment includes Cord Blood and Tissue Storage and Clinical Trials and Biological Services Logistics. It generates maximum revenue from the Clinical Trials and Biological Services Logistics segment. Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns and biological services.

Cryosite (ASX:CTE) Headlines

No Headlines